Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

Helen F. Graham Cancer Center
& Research Institute

Neuro-oncology

The Helen F. Graham Cancer Center & Research Institute’s Neuro-oncology Multidisciplinary Center specializes in treating cancers of the:

  • Brain.
  • Spinal cord.
  • Nervous system.

Your multidisciplinary team

Our patients benefit from the very latest internal-radiation therapy that targets tumor sites with pinpoint precision while minimizing exposure to healthy surrounding tissues. Examples include stereotactic radiosurgery and fractionated stereotactic radiation therapy, which deliver high-dose radiation directly to benign or malignant brain tumors or blood-vessel malformations. These procedures are non-invasive and performed on an outpatient basis.

Surgery, chemotherapy and radiation are used, often in combination, to treat neurological cancers. New procedures under investigation are also available to qualified patients. One example is the use of liquid radioactive iodine delivered through a balloon catheter to help stop tumor regrowth after surgery. These and other new advances, carried out by a team of specially trained neurosurgeons and radiation oncologists, are offered to patients who consent to participate in our strictly regulated clinical research program.

When you visit the Helen F. Graham Cancer Center & Research Institute, you will meet with a team of doctors in one visit:

  • Your surgeon can order diagnostic tests, perform a biopsy to see if your tumor is malignant or operate to remove cancer if necessary.
  • Your medical oncologist can administer chemotherapy or immunotherapy that kills cancer cells.
  • Your radiation oncologist can pinpoint places where your cancer is growing and use precisely focused X-rays to reduce or destroy it.

Together, these specialists, in consultation with your primary-care doctor and with the support of your care-management team, will work with you to create the most appropriate and effective plan of treatment for your cancer.

Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Newark, DE 19713 directions
302-623-4500